Download PDF
Thromb Haemost 1987; 57(02): 187-190
DOI: 10.1055/s-0038-1651091
Original Article
Schattauer GmbH Stuttgart

In Vitro and In Vivo Pharmacological Profiles of the PAF Receptor Antagonist SRI 63-675

Dean A Handley
The Platelet Department, Sandoz Research Institute, East Hanover, N.J., USA
,
Ronald G Van Valen
The Platelet Department, Sandoz Research Institute, East Hanover, N.J., USA
,
Christine M Winslow
The Platelet Department, Sandoz Research Institute, East Hanover, N.J., USA
,
John C Tomesch
The Platelet Department, Sandoz Research Institute, East Hanover, N.J., USA
,
Robert N Saunders
The Platelet Department, Sandoz Research Institute, East Hanover, N.J., USA
› Author Affiliations
Further Information

Publication History

Received 02 October 1986

Accepted after revision 08 January 1987

Publication Date:
28 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

We have examined a recently developed PAF antagonist SRI 63-675 (dimethyl-tetrahydrofuran-methoxyphosphinyloxy-ethylquinolinium) for its ability to inhibit several major PAF-induced physiological responses. The compound was a potent inhibitor of PAF-induced platelet aggregation in platelet rich plasma obtained from humans, guinea pigs, and rabbits, with IC50 values of 3.43, 0.25, and 0.97 μM, respectively. SRI 63-675 did not inhibit ADP, collagen nor epinephrine-induced human platelet aggregation. The IC50 for inhibition of PAF receptor binding to human platelets was 0.37 μM. In the rat SRI 63-675 inhibited 0.1 μg kg-1 i.v. PAF-induced hypotension, with an ED50 of 32 μg kg-1 i.v. Using the same PAF challenge in the guinea pig, SRI 63-675 inhibited the hemoconcentration (ED50 = 17 μg kg-1 i.v.) and bronchoconstriction (ED50 = 24 μg kg-1 i.v.) responses. In the primate, the ED50 was 28 μg kg-1 i.v. against 3.5 μg kg-1 PAF-induced hemoconcentration. The ratio (1:6) in the primate of PAF used (6.3 nmol kg-1) to antagonist at the ED50 (40.7 nmol kg-1) indicates exceptional potency of SRI 63675 in this species. The inhibition by SRI 63-675 of the major PAF-induced effects in the rat, guinea pig and primate suggests a common receptor may be involved in the expression of these PAF responses.

Keywords

Platelet-activating factor - Guinea pig - Rat - Primate - Hemoconcentration - Bronchoconstriction - Receptor antagonist
 

  • References

  • 1 Vargaftig BB, Benveniste J. Platelet-activating factor today. Trends Pharmacol Sci 1983; 341-343
    PubMedGoogle Scholar
  • 2 Humphrey DM, Hanahan DJ, Pinckard RN. Induction of leukocytic infiltrates in rabbit skin by acetyl glyceryl ether phosphorylcholine. Lab Invest 1982; 47: 227-234
    PubMedGoogle Scholar
  • 3 Wedmore CV, Williams TJ. Platelet-activating factor (PAF), a secretory product of polymorphonuclear leukocytes, increases vascular permeability in rabbit skin. Br J Pharmacol 1981; 74: 916P-918P
    PubMedGoogle Scholar
  • 4 Tanaka S, Kasuya Y, Masuda Y, Shigenobu K. Studies of the hypotensive effects of platelet activating factor (PAF, l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits and dogs. J Pharm Dyn 1983; 6: 866-874
    CrossrefPubMedGoogle Scholar
  • 5 Blank ML, Synder F, Byers LW, Brooks B, Muirhead EE. Antihypertensive activity of an alkyl ether analogue of phosphorylcholine. Biochem Biophys Res Comm 1979; 90: 1194-1200
    CrossrefPubMedGoogle Scholar
  • 6 Vargaftig BB, Lefort J, Chignard M, Benveniste J. Platelet-activating factor induces platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol 1980; 65: 185-189
    CrossrefPubMedGoogle Scholar
  • 7 Denjean A, Amoux B, Masse R, Lockhart A, Benveniste J. Acute effects of intratracheal administration of platelet-activating factor in baboons. J Appl Physiol 1983; 55: 799-804
    CrossrefPubMedGoogle Scholar
  • 8 Sanchez-Crespo M, Alonso F, Inarrea P, Alvarez V, Egido J. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: Evidence for a platelet independent mechanism. Immunopharmacology 1982; 4: 173-172
    CrossrefPubMedGoogle Scholar
  • 9 McManus LM, Pinckard RN, Fitzpatrick FA, O’Rourke RA, Crawford MH, Hanahan DJ. Acetyl glyceryl ether phosphoryl-choline. Intravascular alterations following intravenous infusion into the baboon Lab Invest 1981; 45: 303-309
    PubMedGoogle Scholar
  • 10 Handley DA, Van Valen RG, Melden MK, Saunders RN. Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. Thromb Haemost 1984; 52: 34-36
    PubMedGoogle Scholar
  • 11 Handley DA, Arbeeny CM, Lee ML, Van Valen RG, Saunders RN. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology 1984; 8: 137-142
    CrossrefPubMedGoogle Scholar
  • 12 Handley DA, Lee ML, Saunders RN. Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemocon-centration in the guinea pig. Thromb Haemost 1985; 54: 756-759
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Pinckard RN. Platelet-activating factor. Hospit Pract 1983; 70: 67-76
    PubMedGoogle Scholar
  • 14 Handley DA, Saunders RN. Platelet activating factor and inflammation in atherosclerosis: Targets for drug development. Drug Devel Res 1986; 6: 361-375
    PubMedGoogle Scholar
  • 15 Doebber TW, Wu MS, Robbins JC, MaChoy B, Chang M N, Shen TY. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone Biochem Biophys Res Comm 1983; 127: 799-808
    PubMedGoogle Scholar
  • 16 Shen TY, Hwang SB, Chang MN, Doebber TW, Lam M HT, Wu MS, Wang X, Han GQ, Li RZ. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. Proc Natl Acad Sci USA 1985; 82: 672-676
    CrossrefPubMedGoogle Scholar
  • 17 Hwang SB, Lam MH, Li CL, Shen TY. Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema. Eur J Pharmacol 1986; 120: 33-41
    CrossrefPubMedGoogle Scholar
  • 18 Hwang S-B, Li C-H, Lam M-H, Shen TY. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. Lab Invest 1985; 52: 617-630
    PubMedGoogle Scholar
  • 19 Terashita Z, Taushima S, Yoshioka Y, Nomura H, Inada Y, Nishikawa K. CV-3988 - A specific antagonist of platelet-activating factor (PAF). Life Sci 1983; 32: 1975-1981
    CrossrefPubMedGoogle Scholar
  • 20 Terashita Z, Imura Y, Nishikawa K, Sumida S. Is platelet activating factor (PAF) a mediator of endotoxin shock?. Eur J Pharmacol 1985; 109: 257-263
    CrossrefPubMedGoogle Scholar
  • 21 Issekutz HC, Spedjda M. Evidence that platelet activating factor may mediate some acute responses. Studies with the platelet-activating factor antagonist, CV-3988. Lab Invest 1986; 54: 275-281
    PubMedGoogle Scholar
  • 22 Handley DA, Farley C, Deacon RW, Saunders RN. Evidence for district systemic extravasation effects of platelet activating factor, leukotrienes B4, C4, D4 and histamine in the guinea pig. Prostaglandins, Leukotrienes Med 1986; 21: 269-277
    CrossrefPubMedGoogle Scholar
  • 23 Handley DA, Van Valen RG, Saunders RN. Vascular responses of platelet activating factor in the cebus apella primate and inhibitory profiles of antagonists SRI 63-072 and SRI 63-119. Immunopharmacology 1986; 11: 175-182
    CrossrefPubMedGoogle Scholar
  • 24 Handley DA, Van Valen RG, Melden MK, Flury S, Lee MM, Saunders RN. Inhibition and reversal of endotoxin, aggregated IgG-and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist. Immunopharmacology 1986; 12: 11-16
    CrossrefPubMedGoogle Scholar
  • 25 Patterson R, Harris KE, Lee ML, Houlihan WJ. Inhibition of rhesus monkey airway and cutaneous responses to platelet-activating factor (PAF) (AGEPC) with the anti-PAF agent SRI 63-072. Inti Arch Aller Appl Immunol 1986; 81: 265-268
    PubMedGoogle Scholar
  • 26 Hseuh W, Gonzales-Crussi F, Arroyave JL, Anderson RC, Lee ML, Houlihan WJ. Platelet activating factor-induced ischemic bowel necrosis: The effect of PAF antagonists. Eur J Pharmacol 1986; 123: 79-83
    CrossrefPubMedGoogle Scholar
  • 27 Sanches-Crespo M, Fernandes-Gallardo S, Nieto ML, Baranes J, Barquet P. Inhibition of the vascular actions of immunoglobulin G aggregates by BN 52021, a highly specific antagonist of PAF-acether. Immunopharmacology 1985; 10: 69-75
    CrossrefPubMedGoogle Scholar
  • 28 Etienne A, Hecquet F, Soulard C, Spinnewyn B, Clostre F, Braquet P. In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific paf-acether antagonist: BN 52021. Agents Actions 1985; 17: 368-371
    PubMedGoogle Scholar
  • 29 Desquend S, Touray C, Randon J, Lagente V, Vilain B, Maridonneau-Parini I, Etienne A, Lefort J, Braquet P, Vargaftig BB. Interference of BN 52021 (Gingkolide B) with bronchopulmonary effects of PAF-acether in the guinea pig. Eur J Pharmacol 1986; 127: 83-92
    CrossrefPubMedGoogle Scholar
  • 30 Miyamoto T, Ohno H, Yano T, Okada T, Hamanaka N, Kawasaki A. ONO-6240: A new potent antagonist of platelet-activating factor. Adv Prostaglandins, Thromboxane, Leukotriene Res 1985; 15: 719-720
    PubMedGoogle Scholar
  • 31 Toyofuka T, Kubo K, Kobayashi T, Kusama S. Effects of ONO-6240, a platelet-activating factor antagonist, on endotoxin shock in unanesthetized sheep. Prostaglandins 1986; 31: 271-280
    CrossrefPubMedGoogle Scholar
  • 32 Handley DA, Tomesch JC, Saunders RN. Inhibition of PAF-induced responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. Thromb Haemost 1986; 56: 40-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Handley DA, Van Valen RG, Tomesch JC, Melden MK, Jaffe JM, Ballard FH, Saunders RN. Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog. Immunopharmacology. 1987 (in press)
    PubMedGoogle Scholar
  • 34 Doebber TW, Wu MS, Biftu T. Platelet activating factor (PAF) mediation of rat anaphylatic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731. J Immunol 1986; 136: 4659-4668
    PubMedGoogle Scholar
  • 35 Hwang SB, Lam MH, Biftu T, Beattie TR, Shen TY. Trans-2-5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. J Biol Chem 1985; 260: 15639-15645
    PubMedGoogle Scholar
  • 36 Camussi G, Tetta D, Deregibus M, Bussolino F, Vercellone A. Platelet activating factor (paf-acether) in experimentally-induced rabbit acute sickness. Role of basophil-derived paf-acether in immune complex deposition. J Immunol 1982; 128: 86-94
    PubMedGoogle Scholar
  • 37 Winslow CM, Anderson RC, D’Aries FJ, Frisch GE, De Lillo AK, Lee ML, Saunders RN. Toward understanding the mechanism of action of platelet activating factor receptor antagonists. In New Horizons in Platelet Activating Factor Research Winslow CM, Lee ML. (eds.) John Wiley and Sons; Chichester: 1987. pp 153-164
    Google Scholar
  • 38 Toth PD, Mikulaschek AW. Effects of platelet-activating factor antagonist, CV-3988, on different shock models in the rat. Circ Shock 1987; 20: 193-204
    PubMedGoogle Scholar
  • 39 Braquet P, Touqui L, Vargaftig BB, Shen TY. Perspectives in platelet activating factor research. J Med Chem. (in press)
    PubMedGoogle Scholar